Peripheral arteriography with a new nonionic agent: comparison of iomeprol with iopamidol. 1994

U Ugolotti, and P Larini, and C Marcato, and F Cusmano, and F Puccianti
Istituto di Scienze Radiologiche, Università di Parma, Italy.

Aim of this randomized, double-blind, parallel group study was to compare the safety, tolerance and diagnostic efficacy of iomeprol and iopamidol, both at iodine concentration of 150 mgI/ml, in 100 adult patients undergoing peripheral intra-arterial digital subtraction angiography (IA-DSA). All patients underwent extensive pre- and post-contrast clinical, instrumental and laboratory evaluation for safety assessments. The tolerance to the test compounds was evaluated in terms of discomfort associated with the injection of the test compounds. Image quality was prospectively graded by two independent readers according to a five-point scale as 1, insufficient; 2, sufficient; 3, good; 4, excellent; or E, excessive. At the end of the study, two experienced radiologists working at institutions other than the study centre and not aware of patients identity, clinical profile or results of other imaging procedures, jointly evaluated study images using the same ordinal scale. The procedure was always well tolerated. None of the studied patients experienced adverse events. All angiographic examinations were rated as diagnostic. The quality of the radiographs was judged as excellent or good in most individual patient studies, without significant differences between the two study groups. No significant differences between the results of prospective on-site assessment and retrospective external assessment were detected. The results of our study show that iomeprol and iopamidol are equally effective, well tolerated and safe contrast agents when used for peripheral IA-DSA.

UI MeSH Term Description Entries
D007479 Iopamidol A non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiological procedures. B-15,000,B-15000,Gastromiro,Iopamidol, (+-)-Isomer,Iopamidol, (R)-Isomer,Iopamidol, Sodium Salt, (S)-Isomer,Iopamiro,Isovue,Isovue 370,Jopamidol,Niopam,SQ 13,396,Solutrast,Solutrast 370,Solutrast Gastro,B 15,000,B 15000,B15,000,B15000
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D011856 Radiographic Image Enhancement Improvement in the quality of an x-ray image by use of an intensifying screen, tube, or filter and by optimum exposure techniques. Digital processing methods are often employed. Digital Radiography,Image Enhancement, Radiographic,Radiography, Digital,Enhancement, Radiographic Image,Enhancements, Radiographic Image,Image Enhancements, Radiographic,Radiographic Image Enhancements
D003287 Contrast Media Substances used to allow enhanced visualization of tissues. Radiopaque Media,Contrast Agent,Contrast Agents,Contrast Material,Contrast Materials,Radiocontrast Agent,Radiocontrast Agents,Radiocontrast Media,Agent, Contrast,Agent, Radiocontrast,Agents, Contrast,Agents, Radiocontrast,Material, Contrast,Materials, Contrast,Media, Contrast,Media, Radiocontrast,Media, Radiopaque
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D004361 Drug Tolerance Progressive diminution of the susceptibility of a human or animal to the effects of a drug, resulting from its continued administration. It should be differentiated from DRUG RESISTANCE wherein an organism, disease, or tissue fails to respond to the intended effectiveness of a chemical or drug. It should also be differentiated from MAXIMUM TOLERATED DOSE and NO-OBSERVED-ADVERSE-EFFECT LEVEL. Drug Tolerances,Tolerance, Drug,Tolerances, Drug
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

U Ugolotti, and P Larini, and C Marcato, and F Cusmano, and F Puccianti
June 1985, Journal of the Canadian Association of Radiologists,
U Ugolotti, and P Larini, and C Marcato, and F Cusmano, and F Puccianti
October 1982, Radiology,
U Ugolotti, and P Larini, and C Marcato, and F Cusmano, and F Puccianti
February 1984, AJR. American journal of roentgenology,
U Ugolotti, and P Larini, and C Marcato, and F Cusmano, and F Puccianti
January 1982, Cardiovascular and interventional radiology,
U Ugolotti, and P Larini, and C Marcato, and F Cusmano, and F Puccianti
February 1985, Journal of the American College of Cardiology,
U Ugolotti, and P Larini, and C Marcato, and F Cusmano, and F Puccianti
September 1992, Angiology,
U Ugolotti, and P Larini, and C Marcato, and F Cusmano, and F Puccianti
December 1983, Rinsho hoshasen. Clinical radiography,
U Ugolotti, and P Larini, and C Marcato, and F Cusmano, and F Puccianti
September 1985, American heart journal,
U Ugolotti, and P Larini, and C Marcato, and F Cusmano, and F Puccianti
May 1994, Investigative radiology,
U Ugolotti, and P Larini, and C Marcato, and F Cusmano, and F Puccianti
December 1983, Annales de radiologie,
Copied contents to your clipboard!